The ACOT1, ACOT2, and ACOT4 encoded enzymes are type I acyl-CoA thioesterases while the ACOT7, ACOT8, ACOT9, ACOT11, ACOT12, ACOT13, THEM4, and THEM5 encoded enzymes are type II acyl-CoA thioesterases
Published clinical research has characterised the compound in controlled trials: a Phase 2 obesity trial reported dose-dependent body-weight change in the study population (Jastreboff et al., 2023), and a separate Phase 2 trial investigated the GIP/GLP-1/glucagon agonist in people with type 2 diabetes (Rosenstock et al., 2023)
It depends on sustained receptor activation throughout the week
Introduction Hepatic enzyme induction may be associated with changes in liver weight, histological evidence of abnormal hepatocytes, alteration of serum clinical chemistry analytes (Ennulat et al